Health Economics›Pancreatic NET›All lines of therapy

All lines of therapy

Pancreatic NET · 17 regimens

Cost estimates only — modelled on a typical patient (BSA 1.7 m², 70 kg, CrCl 90 mL/min) using the cheapest available formulary presentation. Excludes vial wastage, facility fees, supportive care, and infusion consumables. Not for billing, formulary decisions, or clinical use.

Filters

Y-axis

Cost vs Efficacy · 6 points

Fully pricedPartial pricing

Regimen	Biomarker	Cost/cycle ↓	Cycle	PFS ↕	OS ↕	Est. cycles	Course cost ↕	Evidence
Everolimus and Octreotide Variant #01	—	R 46 352	28d	~16.4 mo	—	~2	~R 92 704 PFS proxy · indirect	1
Temozolomide and Bevacizumab Variant #01	—	R 43 070	28d	—	—	~2	~R 86 139 indirect	—
Sunitinib monotherapy Variant #01	—	R 33 433	42d	~12.6 mo	~38.6 mo	~2	~R 49 300 PFS proxy · indirect	2
Lanreotide Depot/Autogel monotherapy Variant #01	—	R 28 667	28d	—	—	~24	~R 688 013 PFS proxy · indirect	1
Octreotide LAR monotherapy Variant #01	—	R 27 992	28d	~8.5 mo	~36.3 mo	~2	~R 55 984 PFS proxy · indirect	3
Lutetium Lu 177 dotatate and Octreotide LAR Variant #01 Partial	—	R 27 992	28d	~22.8 mo	~48.0 mo	~2	~R 55 984 PFS proxy · indirect	3
Temozolomide and Thalidomide Variant #01	—	R 26 984	28d	—	—	~2	~R 53 967 indirect	—
Everolimus monotherapy Variant #01	—	R 18 360	28d	~11.0 mo	~44.0 mo	~2	~R 36 719 PFS proxy · indirect	2
Octreotide monotherapy Variant #04	—	R 15 464	—	—	—	~2	~R 30 928 indirect	—
Temozolomide monotherapy Variant #02	—	R 7 358	14d	~4.0 mo	~16.3 mo	~26	~R 129 994 PFS proxy · indirect	10
Capecitabine and Temozolomide Variant #01	—	R 5 684	28d	—	—	~2	~R 11 369 indirect	—
Doxorubicin and Streptozocin Variant #01 Partial	—	R 1 014	42d	—	—	~2	~R 2 029 indirect	—
FAS Variant #01 Partial	—	R 754	28d	—	—	~2	~R 1 508 indirect	—
Fluorouracil and Streptozocin Variant #01 Partial	—	R 303	42d	—	~24.3 mo	~2	~R 607 PFS proxy · indirect	—
Octreotide and Interferon alfa Variant #01 Partial	—	—	7d	—	—	~2	—	—
Lanreotide and Interferon alfa-2b Variant #01 Partial	—	—	7d	—	—	~2	—	—
Placebo Partial	—	—	—	4.4 mo	—	—	—	3

17 of 17 regimens shown